Most Blood Pressure Drugs Are Targeting the Wrong Biology.
Here Is How to Find Out If Yours Is One of Them.
Your blood pressure can look controlled on paper while your cardiovascular risk keeps climbing.
A review series published this month in Circulation Research addresses exactly that. Scientists at Vanderbilt University open with a fact most patients never hear: many people whose blood pressure and lipid levels appear well controlled still go on to experience heart attacks, strokes, and heart failure.
I have been writing about this biology for over two decades. In Superhuman, I laid out why cardiovascular disease kills people who look fine on paper and what to measure instead. What is in this review series is evidence now moving in the direction of the framework I learned in my 30s, when I spent time with researchers in their 70s and 80s who had spent careers watching what happened to patients when you looked past the numbers. They were treating the biological mechanisms raising blood pressure, not just the reading. Their ideas were well ahead of the published literature.
The field is now moving in their direction.
The series frames where cardiology stands right now as the third era of hypertension treatment. The first era, beginning in the 1950s, focused on lowering blood pressure with diuretics and beta-blockers. The second era, from the 1980s, introduced mechanism-based targeting of the RAAS (renin-angiotensin-aldosterone system: the hormonal network governing blood pressure and fluid balance) with drugs like captopril and losartan. Both produced major advances. The new framework goes deeper, into vascular aging, chronic inflammation, and the body’s failure to repair its own blood vessels, and the interactions between them.
If you have been following my work, you have been working on that deeper biology for years, through anti-inflammatory nutrition, fasting, full biomarker testing, and hormone optimization.
In the full version you’ll get:
The specific biological pathways this series identifies, and how to find out which one may be driving your risk
Why a class of drugs originally approved for diabetes is now reducing heart attacks through mechanisms that go beyond blood sugar control
What autonomous aldosterone production may be doing in up to 30% of older patients with hypertension, even when standard labs look fine
The tests to request and what each result points to
[Subscribe to unlock the full protocol]
